tiprankstipranks
Theravance Biopharma (TBPH)
NASDAQ:TBPH
US Market

Theravance Biopharma (TBPH) Income Statement

Compare
311 Followers

Theravance Biopharma Income Statement

Last quarter (Q3 2024), Theravance Biopharma's total revenue was $16.87M, an increase of 7.49% from the same quarter last year. In Q3, Theravance Biopharma's net income was $-12.70M. See Theravance Biopharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 57.42M$ 51.35M$ 55.31M$ 71.86M$ 73.41M
Gross Profit
$ 16.80M$ 44.76M$ 48.02M$ -189.10M$ -145.83M
Operating Expenses
$ 113.46M$ 130.47M$ 292.95M$ 369.61M$ 325.33M
Depreciation and Amortization
$ 6.05M$ 6.59M$ 7.29M$ 6.64M$ 6.52M
EBITDA
$ -40.87M$ -79.86M$ -249.39M$ -294.00M$ -203.29M
Operating Income
$ -56.03M$ -91.96M$ -257.78M$ -297.76M$ -251.91M
Other Income/Expenses
$ 6.77M$ -858.00K$ -7.44M$ 11.22M$ 10.24M
Pretax Income
$ -49.27M$ -92.81M$ -199.58M$ -286.54M$ -241.68M
Net Income
$ -55.19M$ -92.82M$ -199.43M$ -278.02M$ -236.46M
Per Share Metrics
$ ―$ ―$ ―$ ―$ ―
Basic EPS
$ -1.00$ -1.26$ -2.87$ -4.46$ -4.25
Diluted EPS
$ -1.00$ -1.26$ -2.87$ -4.46$ -4.25
Weighted Average Shares Outstanding
55.30M 73.59M 69.46M 62.34M 55.61M
Weighted Average Shares Outstanding (Diluted)
55.30M 73.59M 69.46M 62.34M 55.61M
Currency in USD

Theravance Biopharma Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis